The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AVIR | +33.01% | -95.39% | -45.95% | -87% |
| S&P | +15.49% | +82.14% | +12.74% | +113% |
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
Roche calls it quits on the duo's attempt to develop an oral COVID-19 therapy.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$104.00K | 0.0% |
| Market Cap | $230.14M | -18.6% |
| Market Cap / Employee | $4.11M | 0.0% |
| Employees | 56 | 0.0% |
| Net Income | -$42,049.00K | -35.0% |
| EBITDA | -$45,463.00K | -22.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $77.34M | -21.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $213.00K | -79.6% |
| Short Term Debt | $832.00K | 5.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -35.26% | -3.6% |
| Return On Invested Capital | -13.13% | 6.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$40,375.00K | -75.3% |
| Operating Free Cash Flow | -$40,375.00K | -75.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.62 | 0.58 | 0.75 | 0.65 | 8.78% |
| Price to Tangible Book Value | 0.62 | 0.58 | 0.75 | 0.65 | 8.78% |
| Enterprise Value to EBITDA | 4.37 | 4.35 | 1.87 | 2.18 | -59.23% |
| Return on Equity | -33.9% | -30.5% | -32.4% | -38.0% | 13.52% |
| Total Debt | $1.64M | $1.45M | $1.25M | $1.05M | -43.05% |
No podcast episodes available.
AVIR earnings call for the period ending June 30, 2022.
AVIR earnings call for the period ending March 31, 2022.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
